Abcam, ab229378, Anti-ENO1 antibody [EPR19758] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ENO1 antibody. Carrier free. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19758,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:Flow Cyt (Intra), IHC-P, IP, WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:ab229378 does not cross-react with ENO2 or ENO3.

Product details:
ab229378 is the carrier-free version of
ab227978
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Enolase 1 or alpha-enolase is an important enzyme in the glycolytic pathway. It catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. We also refer to it as an enolase reaction. ENO1 protein has a molecular mass of approximately 47 kDa and is expressed in most tissues but found most abundantly in the brain muscle and liver. Additionally ENO1 can exist in both cytosolic and plasma membrane-associated forms playing functional roles in different cellular contexts.
Biological function summary
The ENO1 protein serves multiple functions beyond its glycolytic activity. It also acts as a plasminogen receptor on the cell surface aiding in the modulation of pericellular and extracellular matrix degradation processes. Through this role ENO1 influences cell migration and tissue remodeling. This protein can form part of larger protein complexes contributing to its versatility in various cellular functions.
Pathways
ENO1 plays a critical role in glycolysis a central metabolic pathway that converts glucose into pyruvate generating ATP as a result. In this pathway ENO1 closely interacts with other enzymes like phosphoglycerate kinase and pyruvate kinase. Additionally as a plasminogen receptor ENO1 links to the plasminogen activation pathway affecting fibrinolysis and cellular response to tissue injury.
ENO1 is associated with cancer and neurodegenerative diseases. Overexpression or aberrant regulation of ENO1 often correlates with tumor progression and metastasis in cancers such as lung and breast cancer. In neurodegenerative disorders like Alzheimer's disease abnormal functioning of ENO1 can impact brain energy metabolism and neuron degeneration. ENO1's interaction with other proteins such as beta-enolase further connects it to these conditions influencing disease mechanisms and patient outcomes.